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Mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease of
the mucous membranes, which can cause irreversible scarring and is discussed
to be associated with cancer, if laminin-332-autoantibodies are present. MMP
with severe ocular and laryngeal involvement is difficult to treat and can be
treatment-refractory to conventional immunosuppressant therapy. A 67-year-old man
with a history of prostate cancer presented to our clinic with sore throat, intraoral
bullae, odynophagia, dysphonia, exertional dyspnea, and erosions of the glans penis.
Clinical examination confirmed a laryngo-pharyngitis with involvement of the epiglottis
and bilateral symblepharon. Diagnostics comprising multiple biopsies, direct and indirect
immunofluorescence, serology analysis, and immunoblotting confirmed the diagnosis of
a paraneoplastic MMP by showing a subepithelial split in histology and the presence
of anti-laminin-332-antibodies. Despite combined systemic treatment with prednisolone
and either dapsone or azathioprine, a progress of the disease occurred leading
to severe ocular and laryngeal complications. Two month after rituximab treatment,
complete disease control was achieved. This case report shows a severe ocular and life
threatening laryngeal involvement of therapy-refractory paraneoplastic MMP highlighting
the importance of interdisciplinary management and difficulty of diagnosing MMP despite
repeated diagnostic testing.
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BACKGROUND
Mucous membrane pemphigoid (MMP) is defined as a heterogeneous group of autoimmune,
chronic inflammatory blistering diseases, which lead to subepithelial bullae predominantly of
the mucous membranes and occasionally the skin (1–3). The most common affected sites are
the oral and ocular mucosae, but an involvement of the nasopharynx, esophagus, larynx, and
anogenital region may also occur. The underlying pathophysiology is characterized by a linear
deposition of IgG, IgA, or C3 along the epithelial basement membrane zone (1). If MMP is
suspected clinically, diagnostic testing and treatment is required without delay in order to prevent
complications like irreversible scarring potentially leading to blindness, airway stenosis, esophageal,
and anogenital stricture (3). Smaller studies and case reports suggest positive laminin-332
(laminin-5)-autoantibodies to be associated with a paraneoplastic manifestation of MMP (4–7).
Epidemiological studies of MMP are rare. Thus, the real world incidence of MMP remains
unknown. In the literature the incidence in United Kingdom of cicatricial conjunctivitis was
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calculated as 0.8 per million, whereas the incidence of MMP in
France and Germany was estimated to be 1.3–2.0 per million per
year (8–10).
Therapy of MMP is mainly dependent on the classification
of high and low risk disease. Low risk MMP (involvement of
oral mucosae and skin) should be treated initially by topical
steroids whereas it is recommended to treat high risk MMP
(involvement of the eyes, esophagus, larynx, urogenital region)
by systemic corticosteroids. In case of incomplete disease control,
dapsone in combination with immunosuppressive therapies
like azathioprine, cyclophosphamide, or mycophenolate mofetil
should be applied (1). According to the European guideline
for management and treatment of bullous pemphigoid,
rituximab is recommended as third-line therapy, if conventional
immunosuppressive drugs were not effective, contraindicated, or
showed unacceptable side effects (11). In the literature, rituximab
has been described effective as treatment in therapy-recalcitrant
MMP (12–16). However, relapse is frequent and only a few
studies including a small quantity of patients are available
(12–16).
Herewith we present a case of aMMPwith a positive history of
cancer, severe laryngeal, ocular, and genital involvement showing
a refractory course of the disease on azathioprine and dapsone
immunosuppressive treatment. Given the severe involvement
of the eyes and epiglottis we emphasize the indispensable
multidisciplinary management of paraneoplastic MMP.
CASE PRESENTATION
A 67-year-old caucasian male patient presented first to the Clinic
for Dermatology in August 2017 suffering sinceMarch 2017 from
sore throat, intraoral bullae, odynophagia, dysphonia, exertional
dyspnea, and erosions of the glans penis. He was first treated by
his general practitioner for a suspected oral herpes infection with
antiviral medication without improvement. At the onset of the
symptoms the patient had been retired.
FIGURE 1 | Bronchoscopy showing multiple ulcers of the pharynx, highly vulnerable mucous membranes and granulomatous changes of the vocal cords.
The medical history of the patient revealed a history of
prostate cancer diagnosed and treated by radical prostatectomy
∼1 year before the onset of symptoms, epilepsy treated with
levetiracetam since 2002, asthma and a chronic rhinosinusitis
since 1988 treated with surgery.
The clinical examination revealed dry mucuous membranes
in the oral cavity with erosions and swellings of the buccal
mucosa and the hard palate. Inspection of the pharynx showed
a distinct laryngo-pharyngitis with involvement of the epiglottis.
To exclude an involvement of trachea a bronchoscopy was
done revealing multiple ulcers of the pharynx, highly vulnerable
mucous membranes and granulomatous changes of the vocal
cords (Figure 1).
A biopsy, taken shortly before the first presentation to our
clinic in an external hospital showed a subepithelial split together
with an inflammatory cell infiltration comprising monocytes
and granulocytes. The DIF analysis was negative. In our clinic
an additional biopsy of the oral mucous membrane stained
with haematoxylin and eosin staining was done. The result
was negative for MMP showing an increase of collagen fibers
with lymphohistiocytic infiltrate and an increased amount of
plasma cells in the corium. The DIF analysis revealed unspecific
perivascular C3 deposits. Consistent with the first biopsy, a
third biopsy with haematoxylin and eosin staining, showed a
subepithelial split (Table 1). Indirect immunofluorescence using
both monkey esophagus and human salt-split skin did not
detect circulating IgG- or IgA-autoantibodies. In addition, serum
analysis using ELISA with recombinant BP180 NC16A, BP180,
BP230, and desmoglein 1 and 3 was negative (Table 2). As
serology testings were negative, immunoblotting of extracellular
matrix was performed, which was positive for circulating IgG4-
autoantibodies to γ2-chain of laminin-332 (Figure 2). The
differential diagnosis of Behçet’s disease presenting orogenital
ulceration was unlikely as the patient only fulfilled one minor
criteria, did not show characteristic histological changes for
Behçet’s disease or any other major or minor criteria for Behçet’s
disease. Accordingly, clinical criteria such as uveitis or retinal
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TABLE 1 | Histological findings of performed biopsies.
Biopsy No. Hematoxylin and eosin
staining
DIF analysis
1 Subepithelial split together with




2 Increase of collagen fibers with
lymphohistiocytic infiltrate and an
increased amount of plasma
cells in the corium
Negative
3 Subepithelial split Not done
TABLE 2 | Laboratory findings.
















vasculitis, characteristic skin lesions, HLA-typing for B51 and
pathergy test were negative. The differential diagnosis of a
cytotoxic-mediated disease like Stevens-Johnson-Syndrome was
rather unlikely, given the course of the disease, the affected sites,
the lack of a possible trigger and the histological findings without
signs of a CD8+-mediated reaction like an interface dermatitis or
necrotic keratinocytes. An oral candida infection was excluded
by a swap. Given the positive history for prostate cancer we
performed a tumor staging. The chest-x-ray, ultrasound of
the abdomen and PSA-value (0.1 µg/l) were within normal
limits. Based on the clinical course, the histological finding
and the immunoblot positive for laminin-332-autoantibodies, we
suspected a paraneoplastic MMP.
Due to an acute exacerbation with progressive exertional
dyspnea, anxiety choking, dry cough, hoarseness and ocular
irritation a chest-x-ray, and body plethysmography were
performed to exclude an acute exacerbation of asthma. Because of
exertional dyspnea a laryngoscopy was performed which revealed
progressive oral ulcers as well as a synechia of the first third of the
vocal cords.
Even though the diagnosis could not be confirmed by
immunohistological criteria at the time of the first symptoms,
a paraneoplastic MMP was suspected based on the clinical
manifestation with the positive cancer history. Given both, the
critical laryngal involvement causing dyspnoea and the ocular
bilateral stage 4 symblepharon according to Tauber und Foster
classification (17) (Figure 3), systemic treatment was initiated.
Intravenous methylprednisolone was applied (250 mg/day) at 3
FIGURE 2 | Immunoblotting of extracellular matrix showing circulating
IgG4-autoantibodies to γ2-chain of laminin-332.
FIGURE 3 | Active bilateral stage 4 symblepharon according to Tauber und
Foster classification.
consecutive days. The pulse therapy was repeated for three times
every 4 weeks. Oral therapy with dapsone (100 mg/day), which
had been initiated after the first pulse therapy was discontinued
by the general practitioner due to methemoglobinemia, cyanosis
of the lips, and dyspnoea. Instead a combined oral therapy
comprising azathioprine (100 mg/day) and prednisolone (50
mg/day) was given. Prednisolone was consecutively reduced to
10mg per day. Topical treatment included Hylogel due to ocular
involvement, inhalation of Tacholiquin 1% and a prednisolone-
dexpanthenol solution. Hereafter disease control was achieved
with reduction of hoarsness and dyspnoea. Azathioprine was
discontinued after 4 month due to elevated values of gamma-
glutamyltransferase.
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FIGURE 4 | Post-treatment pictures showing a stable ocular involvement and
no new enoral lesions 5 month after rituximab treatment.
Due to an acute laryngotracheitis with acute dyspnea as
well as inspiratory and expiratory stridor, a microlaryngoscopy
with division of the synechia of the anterior commissure was
performed in the clinic for ear, nose, and throat followed by a
fixation of a silicone sheet.
Given both systemic treatments with azathioprine and
dapsone had to be discontinued due to adverse effects, therapy
with rituximab 1,000mg was initiated twice in a 14-days interval.
The follow-up examination 8 weeks later revealed a stable disease
with no new oral lesions (Figure 4). According to the patient
dyspnea did not appear since the start of rituximab treatment.
The ocular manifestation of the MMP was assessed stable by
the ophthalmologists. During the latest check-up for cancer
no signs of relapse were detected. Differential white blood cell
count was taken during and after the treatment with rituximab.
Initially, total leukocytes and lymphocytes were within normal
limits (Leukocytes: 6.75/nl, lymphocytes: 1.13/nl). 7 weeks after
the second treatment with rituximab a lymphocytopenia was
detected (0.60/nl). Leukocytes and lymphocytes before and after
radical prostatectomy were normal (leukocytes: before 6.44/nl,
after 9.90/nl, lymphocytes: before 1.12/nl, after 1.24/nl)
DISCUSSION
MMP is a rare autoimmune blistering disease, which
predominantly affects the mucous membranes and is
characterized by the linear deposition of IgG, IgA, or C3
along the epithelial basement membrane zone (1). The
diagnosis of MMP is mainly based on clinical manifestation,
immunohistological examination as well as histopathological
and serology analysis like indirect immunofluorescence,
immunoblotting, or immunoprecipitation techniques (3).
According to the consensus conference the clinical course of
disease as well as the DIF analysis are crucial criteria to diagnose
a MMP (1).
Diagnosing MMP can be challenging (18). The diagnosis of
MMP in our patient at the time of the first hospitalization was
made by clinical features only, as the first diagnostic workup
including histology, serology, and immunohistology remained
negative. As the DIF of the biopsy taken in an external hospital
did not show specific changes for MMP, an additional biopsy
was taken from the buccal mucosa. Again, the histology and DIF
analysis did not show characteristic changes forMMP. According
to the literature false-negative results at the first diagnostic
workup of MMP are not rare (18). Repeated testing is highly
recommended to increase the sensitivity of the DIF analysis for
MMP diagnosis (18). However, DIF analysis can show false-
negative results especially in patients with only ocular mucous
membrane involvement or when longstanding lesions are being
analyzed (3, 19). A third biopsy taken of the laryngeal mucosa
showed a subepithelial split in hematoxylin and eosin staining
consistent with the diagnosis of a MMP. Unfortunately an
additional DIF analysis of the third biopsy has not been arranged
by the ENT department. Shimanovich et al. state, that despite
repeated testing up to 5% of the biopsies taken from patients
with MMP remain negative (18). Consistent with our report,
the diagnosis of MMP could be confirmed by the detection of
circulating autoantibodies against bullous pemphigoid antigen
180 or laminin-332 (18).
For ocular MMP Labowsky et al. have shown that patients
showing a linear deposition of IgG, IgA, or C3 at the basement
membrane in a DIF biopsy were more likely to be treated with
systemic immunosuppression compared to patients showing
no linear immunologic deposits at the basement membrane
zone in a DIF biopsy (19). They conclude that even without
confirming the diagnosis by DIF, treatment with systemic
immunosuppression should be initiated (19). In our case
systemic treatment was initiated due to the reduced general
condition of the patient as well as the risk of irreversible
complications due to a delay of intervention. Due to progressive
disease with severe dyspnea and the need of discontinuation of
systemic dapsone and azathioprine therapy, rituximab treatment
was initiated. In the literature, large randomized controlled
studies analyzing rituximab treatment in recalcitrant MMP are
sparse. Lamberts et al. investigated the effectiveness and safety
of rituximab in 28 patients with recalcitrant pemphigoid diseases
(13). Disease control was achieved in the majority of the cases
(67.9%). However, during follow-up, 66.7% patients relapsed.
Repeated treatment with rituximab was effective in 85.7% of
retreated cases. Interestingly, MMP patients showed the most
benefit of rituximab (disease control in 85.7%) compared to
other pemphigoid diseases. However, the rate of relapses was
high (75%). The best outcome was achieved using the high dose
protocol (1,000mg rituximab at days 1 and 15) compared to
the low dose protocol (500mg rituximab) (13). In comparison
to IgG-dominant pemphigoid diseases, rituximab was less
effective in IgA-dominant pemphigoid diseases, representing an
unresponsiveness of IgA positive plasma cells to rituximab (13).
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During the follow-up, 3 patients died of which one was probably
treatment related. Rübsam et al. analyzed 6 MMP patients with
ocular involvement after being treated with rituximab (14). Using
the high dose protocol all patients responded to rituximab.
However, relapse occurred in 83.3% of the cases. Consistent
with the results of Lamberts et al. repeated treatment with
rituximab lead to remission in all patients (14). Two patients
died probably not related to the treatment (14). Heelan et al.
investigated 8 patients with MMP being treated with 1,000mg
rituximab at days 1 and 15 (12). After disease control was
achieved in all patients, a relapse occurred in 100% of the
cases. Retreatment with rituximab lead to a 100% response
rate (12). Shetty et al. published a retrospective study including
case series and case reports of 28 patients with MMP (15).
In this study, different protocols of rituximab treatment were
applied. Consistent with the previous studies a high response
and relapse rate was described (disease control 82.1%, relapse
in >50%) (15). Tomsitz et al. investigated a cohort of 22
patients with recalcitrant autoimmune blistering diseases using
the high dose rituximab protocol (16). Seventy-two percent of
the patients showed a partial or complete remission after the
first cycle. However, unlike the findings of Lamberts et al. the
response rate in patients with MMP was low (40%) (16). In our
case, disease control was achieved 2 month after administering
rituximab using a high dose protocol. Since 5 months after
the treatment no relapse of MMP or adverse effects have been
reported.
Adjuvant treatment with intravenous immunoglobulin or
immunoadsorption in combination with rituximab has been
described effective to treat therapy-refractory MMP (5, 20–
22). Protein A immunoadsorption describes a method to
selectively remove circulating antibodies from the blood in an
extracorporeal circuit (23). It is recommended to be used as
first line treatment in pemphigus vulgaris, pemphigus foeliaceus,
paraneoplastic pemphigus vulgaris, or epidermiolysis bullosa
aquisita (24). Albeit complete disease control was achieved in
our case by rituximab monotherapy, relapse of the disease after
rituximab treatment is frequent in ocular MMP (12). Thus,
protein A immunoadsorption or immunoglobulin treatment
represent a promising alternative to rituximab in case of
recurrence.
The patient presented here had circulating IgG4-
autoantibodies to the γ 2-chain of laminin-332-autoantibodies
determined by immunoblotting analysis. Even though studies
and case reports suggest an association between detection of
laminin-332-autoantibodies and paraneoplastic MMP, Bernard
et al. could not detect a significant relationship in a multicenter
retrospective study (4, 6, 7, 25). The patient’s history was positive
for a prostate cancer diagnosed and treated ∼1 year before the
onset of the first symptoms. A staging examination remained
negative, therefore a direct link between progressive oncological
disease and MMP has not been verified in our case. Further
investigations regarding the interaction of neoplasms and
anti-laminin-332-antibodies are required.
Multidisciplinary management and treatment of the MMP
is of the utmost importance, as different sites can be affected
(1). Unlike the majority of the cases with involvement of the
oral mucosae and the eyes, the patient presented with severe
involvement of the larynx and epiglottis leading to an acute
laryngo-pharyngitis, synechia of the vocal cords and recurrent
episodes of severe dyspnea. On account of the close cooperation
with the clinic for ear, nose, and throat, the division of the
synechia was performed, leading to an improvement of the
symptoms. Herewith we emphasize that the optimal outcome
for the patient was achieved only due to multidisciplinary
management including ENT specialists and ophthalmologists.
A multidisciplinary follow-up is highly recommended to ensure
best disease management.
For the publication of this case report written informed
consent from the patient in accordance with the Declaration of
Helsinki was obtained.
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